tradingkey.logo

Tectonic Therapeutic Inc reports results for the quarter ended June 30 - Earnings Summary

ReutersAug 12, 2025 12:00 PM
  • Tectonic Therapeutic Inc TECX.OQ reported a quarterly adjusted loss of $1.07​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-4.34. The mean expectation of seven analysts for the quarter was for a loss of 98 cents per share. Wall Street expected results to range from $-1.05 to -87 cents per share.

  • Reported revenue was zero​; analysts expected zero.

  • Tectonic Therapeutic Inc's reported EPS for the quarter was a loss of $1.07​.

  • The company reported a quarterly loss of $19.98 million.

  • Tectonic Therapeutic Inc shares had risen by 11.3% this quarter and lost 52.1% so far this year.

FORECAST CHANGES

  • The mean earnings estimate of analysts had risen by about 3.3% in the last three months.​

  • In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

  • Wall Street's median 12-month price target for Tectonic Therapeutic Inc is $76.00, about 70.9% above its last closing price of $22.11

This summary was machine generated from LSEG data August 12 at 11:59 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING

ESTIMATE

ACTUAL

BEAT, MET, MISSED

Jun. 30 2025

-0.98

-1.07

Missed

Mar. 31 2025

-1.09

-0.93

Beat

Dec. 31 2024

-1.39

-0.84

Beat

Sep. 30 2024

-0.82

-1.20

Missed

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI